CardioVascular BioTherapeutics (fka CVBT)

[walhall]

CVBT shareholders – let your voices be heard

With the CVBT shareholders meeting just over a week away, I’m gratified many of us want answers to the three questions I publicly posed for CVBT’s leadership a week ago. No matter what our opinions are on CVBT, all of us can agree that CVBT’s shareholders deserve answers to these questions. In the past however, CVBT has refused to answer these sorts of questions shareholders have posed. The Internet format CVBT has chosen for shareholder meetings prevents all of us from hearing the questions being asked of CVBT’s leadership. No longer. I’m 100% sure that CVBT’s leadership is aware that these questions are being asked, and I am going to post them again here:

1. Since 2016 through today, how much in total equity has CVBT raised? At what price(s) per share? Of the total amount raised, how much came from investors others than CVBT’s CEO Calvin Wallen?

2. At last year’s shareholder meeting, CVBT stated that the Phase II heart clinical trial will be starting in 2019, and the peripheral artery disease trial will be starting in late 2019 or 2020. Yes or no, does CVBT have all the required funding in-hand TODAY to conduct these trials and run the company during this period? If the answer is no, how much in funding is still needed?

3. There are rumors on the message board for many months now that CVBT will be going public again “soon.” Yes or no, will CVBT be going public in 2019?


If you agree that we shareholders deserve these answers, there are two things you can do to help:

A. From now up until the meeting takes place, click on the link below to go to CVBT’s website, copy these three questions below into the message box, and state that as a shareholder you would like CVBT to answer these questions at the shareholders meeting on May 21. Here is the link:
https://www.cvbt.com/contact-us

B. At next week’s shareholders meeting, pose these questions to CVBT management after the company’s presentation is concluded. You can simply copy these questions from here, and then paste them into the shareholders questions submission portal at the meeting. The more shareholders asking these questions, the better.


For the record, I completely reject the notion that CVBT’s leadership has indicated here anonymously that these three uestions can’t be answered because of pending lawsuits. That’s nonsense. CVBT is suing Dan Montano and others for alleged theft of CVBT’s confidential information, and Dan Montano is suing CVBT for unpaid back wages. Do those issues sound anything like the questions being posed? Of course not. It’s kind of like Donald Trump claiming that he can’t release his tax returns because he’s being audited, even while the IRS has publicly stated that there’s nothing about being audited that limits him from releasing his tax returns.

I am very hopeful that CVBT will answer these questions. And if not, stay tuned…

Finally, so as to not disappoint certain individuals on this message board who are frequently trying to find this information, here are the links to the court records in the related Calvin A. Wallen III bankruptcy and fraud cases. Cardiovascular Biotherapeutics CEO, Calvin Wallen III is accused by the U.S. Government Bankruptcy Trustee for Tauren Exploration of stealing $14 million from Tauren and submitting falsified documents to the bankruptcy court to cover his tracks. The trial is scheduled for October 28, 2019:

Tauren Exploration, Inc. Liquidating Trust vs. Calvin Wallen III:
https://www.pacermonitor.com/public/case/24021776/Tauren_Exploration,_Inc_Liquidating_Trust_v_Wallen,_III

Tauren Exploration, Inc. Liquidating Trust vs. Pandale Holdings, Inc. et. al:
https://www.pacermonitor.com/public/case/24021775/Tauren_Exploration,_Inc_Liquidating_Trust_v_Pandale_Holdings,_Inc_et_al

Tauren Exploration, Inc. Liquidating Trust v. Fossil Operating, Inc. et al:
https://www.pacermonitor.com/public/case/24021777/Tauren_Exploration,_Inc_Liquidating_Trust_v_Fossil_Operating_Inc_et_al